# US 2009/0270338 A1 · Diaryl-cyclylalkyl derivatives as calcium channel blockers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0270338 A1
- Document ID: US20090270338A1
- Status: Published application
- Kind: A1
- Application number: 12/430,974
- Filed: 2009-04-28
- Published: 2009-10-29
- Earliest claimed: 2008-04-28
- Inventors: Robert Galemmo, JR.; Richard Holland; Gabriel Hum
- Web page: https://patentgrep.com/patent/US20090270338A1

## CPC

- C07D 295/108: to an acyclic saturated chain
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07C 233/57: having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C 237/42: having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07C 2601/14: The ring being saturated
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds of substituted or unsubstituted N-cyclylalkyl-diphenylpropanamide derivatives as shown in formula (1).

## Claims

### Claim 1

A compound of the formula
or a pharmaceutically acceptable salt or conjugate thereof, wherein
n is 0-3;
each m is independently 0-3;
each R1, R2 and R3 is independently H or selected from the group consisting of an optionally substituted C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, and C6-C12 heteroarylalkyl group, or is selected from halo, CF3, OR, NR2, NROR, NRNR2, SR, SOR, SO2R, SO2NR2, NRSO2R, NRCONR2, NRCOOR, NRCOR, CN, RCN, COOR, CONR2, OOCR, COR, and NO2,
wherein each R is independently H or optionally substituted C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl,
and wherein two R on the same nitrogen atom can be linked to form an optionally substituted 3-8 membered ring, optionally containing one or more N, O or S as ring members;
and wherein the optional substituents on each R group and each ring formed by linking two R groups together, are selected from halo, ═O, ═N—CN, ═N—OR′, ═NR′, OR′, NR′2, SR′, SO2R′, SO2NR′2, NR′SO2R′, NR′CONR′2, NR′COOR′, NR′COR′, CN, COOR′, CONR′2, OOCR′, COR′, and NO2,
wherein each R′ is independently H, C1-C6 alkyl, C2-C6 heteroalkyl, C1-C6 acyl, C2-C6 heteroacyl, C6-C10 aryl, C5-C10 heteroaryl, C7-12 arylalkyl, or C6-12 heteroarylalkyl, each of which is optionally substituted with one or more groups selected from halo, C1-C4 alkyl, C1-C4 heteroalkyl, C1-C6 acyl, C1-C6 heteroacyl, hydroxy, amino, and ═O;
X is C1-C4 alkylene optionally substituted with ═O;
R4 is H or C1-C8 alkyl optionally substituted with ═O;
R5 is selected from the group consisting of H and optionally substituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, —OR6, NR62, and SR6, wherein
each R6 is independently H or C1-C8 alkyl; and
A and B are connected to form a 6-membered non-aromatic, heterocyclic ring which optionally comprises O, S or an additional NR7 as a ring member, wherein
R7 is H or a member selected from the group consisting of C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl group, and sulfonyl, each of which is optionally substituted with up to four R8, CF3, halo, CN, OR8, ═O, C(NR8)NR82, NR82, COR8, COOR8, CONR82, SR8, SOR8, SO2R8, SO2NR82, NR8COOR8, or COCOOR8, wherein
each R8 is independently H, C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C6-C10 aryl, C1-C8 acyl, C2-C8 heteroacyl, C7-C12 arylalkyl, or diarylalkyl, alkylsulfonyl, arylsulfonyl, hydroxy, halo, CF3, each of which may be optionally substituted, and
wherein two R8 groups on the same nitrogen atom can be linked to form a 3 to 8 membered ring, optionally including up to two heteroatoms selected from N, O and S as ring members; or
A is H and B is an a 5-6 membered aromatic or heteroaromatic ring, each optionally substituted with one or more groups selected from R7.

### Claim 2 (depends on 1)

The compound of claim 1, wherein A and B are connected to form a 6-membered non-aromatic, heterocyclic ring which comprises NR7 as a member of the ring, wherein
R7 is as described in claim 1.

### Claim 3 (depends on 2)

The compound of claim 2, wherein
is a group of formula

### Claim 4 (depends on 2)

The compound of claim 2, wherein R7 is C1-C8 alkyl, C2-C4 acyl, phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, or pyrrolyl,
each of which may be optionally substituted with one or more C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C6-C10aryl, C1-C8 acyl, C2-C8 heteroacyl, —OR9, —SR9, —SO2R9, —NR92, halo or CF3, wherein
R9 is H or C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl or C2-C8 heteroalkynyl.

### Claim 5 (depends on 2)

The compound of claim 2, wherein R7 is phenyl, pyridinyl, C1-C6 alkyl or C1-C4 acyl, each of which is optionally substituted with one or more halo, ═O, —CF3, C1-C6 alkyl or C1-C6 aryl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein A is H and B is a 5-6 membered aromatic ring selected from phenyl, pyrimidinyl, pyrazolyl, pyrazinyl, pyridinyl, imidazolyl, furanyl, oxazolyl, isoxazolyl, thiophenyl, isothiazolyl, or thiazolyl, each of which may be optionally substituted with one or more R10, SO2R10, OR10, halo, CF3, or NR112, wherein
R10 is H or C1-C8 alkyl.

### Claim 7 (depends on 1)

The compound of claim 1, wherein each m is independently 0 or 1 and each R1 and R2 is independently selected from C1-C4 alkyl, CF3, halo, and NO2.

### Claim 8 (depends on 1)

The compound of claim 1 wherein X is CH2 or C═O.

### Claim 9 (depends on 1)

The compound of claim 1 wherein R4 is H.

### Claim 10 (depends on 9)

The compound of claim 9, wherein A is H and B is selected from phenyl, pyrazinyl, isoxazolyl, pyridinyl, and thiazolyl, each of which is optionally substituted with one or more CF3, halo, OR8, SO2R8 or R8, wherein
R8 is H or C1-C8 alkyl.

### Claim 11 (depends on 1)

The compound of claim 1 wherein n=3.

### Claim 12 (depends on 1)

The compound of claim 1, which is selected from the group consisting of:

### Claim 13 (depends on 1)

A pharmaceutical composition which comprises the compound of claim 1 in admixture with a pharmaceutically acceptable excipient.

### Claim 14 (depends on 1)

A method to treat a condition mediated by N-type or T-type calcium ion channels, which method comprises
administering to a subject in need of such treatment an amount of the compound of claim 1 or a pharmaceutical composition thereof effective to ameliorate said condition.

### Claim 15 (depends on 14)

The method of claim 14, wherein said condition is chronic or acute pain, mood disorders, neurodegenerative disorders, gastrointestinal disorders, genitourinary disorders, neuroprotection, metabolic disorders, cardiovascular disease, epilepsy, diabetes, prostate cancer, sleep disorders, Parkinson's disease, schizophrenia or male birth control.

### Claim 16 (depends on 14)

The method of claim 14, wherein said condition is chronic or acute pain.
